Kyntra Bio Inc. (NASDAQ: KYNB) received notification from Nasdaq on April 2, 2026, that the company no longer meets continued listing requirements for the Nasdaq Global Select Market.

The biotechnology company failed to comply with the $50 million minimum requirement for total assets and total revenue for the most recently completed fiscal year, according to Nasdaq Listing Rule 5450(b)(3)(A). The deficiency stems from FibroGen International revenue being classified as held for sale in discontinued operations during 2024 and 2025.

Kyntra Bio also does not meet alternative requirements under Listing Rule 5450(b), which include shareholders' equity or market value of listed securities standards.

The notification does not immediately affect the trading status of Kyntra Bio's common stock on Nasdaq. Under exchange rules, the company has 45 days until May 18, 2026, to submit a compliance plan. If Nasdaq accepts the plan, the company may receive an extension of up to 180 days until September 29, 2026, to demonstrate compliance with listing requirements.

The information was disclosed in a company statement regarding the Nasdaq notification.